case_images: PMC9395697_01
case_images: Pericardial effusion after 12 cycles of Nivolumab (Case 1).
case_images: fcvm-09-964324-g0001.jpg
case_images: PMC9395697_01_fcvm-09-964324-g0001.jpg
case_images: F1
case_images: Angiogram showed a mild pericardial effusion and left pleural effusion (Figure 1). An echocardiogram demonstrated a small pericardial effusion, with no evidence of tamponade, consistent with NCI-CTCAE grade 2.
case_images: PMC9395697_02
case_images: Pericardial effusion after 6 cycles of pembrolizumab (Case 2).
case_images: fcvm-09-964324-g0002.jpg
case_images: PMC9395697_02_fcvm-09-964324-g0002.jpg
case_images: F2
case_images: A CT pulmonary angiogram showed an interval pericardial effusion (Figure 2).
case_images: Clinical course of patient with recurrent pericarditis (Case 2).
case_images: fcvm-09-964324-g0003.jpg
case_images: PMC9395697_02_fcvm-09-964324-g0003.jpg
case_images: F3
case_images: The timeline of pembrolizumab treatment related to pericardial disease is shown in Figure 3.